MUMBAI, India, June 26 -- Intellectual Property India has published a patent application (202617027352 A) filed by Enanta Pharmaceuticals, Inc. on March 09, 2026, for Pharmaceutical Compounds And Compositions As C-Kit Kinase Inhibitors.
Inventors include Zhang, Jiajun; Siu, Yuk, Ming; Xu, Peilin; Rhodes, Matthew C.; Cao, Hui; Or, Yat Sun; Gao, Xuri; Li, Wei; Xing, Xuechao; and Mitchell, Scott.
The application for the patent was published on June 19, 2026, under issue no. 25/2026.
Abstract: The invention provides compounds of formulae (I), or pharmaceutically acceptable salts and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors; as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit, CSF1R, and PDGFR (PDGFRa, PDGFRß) kinases.
Disclaimer: Curated by HT Syndication.
